Chronic Kidney Disease Market Report 2026

The chronic kidney disease market size has grown strongly in recent years. It will grow from $74.87 billion in 2025 to $79.43 billion in 2026 at a compound annual growth rate (CAGR) of 6.1%. The growth in the historic period can be attributed to rising prevalence of diabetes and hypertension, increased availability of dialysis infrastructure, improved kidney function diagnostics, growing awareness of chronic renal disorders, expansion of nephrology care services.

The chronic kidney disease market size is expected to see strong growth in the next few years. It will grow to $101.87 billion in 2030 at a compound annual growth rate (CAGR) of 6.4%. The growth in the forecast period can be attributed to increasing development of novel renal therapies, rising demand for patient-centric dialysis options, expansion of digital kidney health monitoring, growing focus on transplant readiness, increasing investments in preventive nephrology. Major trends in the forecast period include increasing emphasis on early ckd detection, rising adoption of renoprotective drug therapies, growing use of home dialysis solutions, expansion of multidisciplinary care models, enhanced focus on slowing disease progression.

The rising prevalence of kidney disease is expected to support the growth of the chronic kidney disease market in the coming years. Kidney diseases encompass a range of conditions that impair the structure and function of the kidneys. Medications used for kidney disease help regulate blood pressure and reduce protein loss, thereby slowing the progression of kidney damage, managing symptoms, and preventing complications. For example, in June 2023, Kidney Research UK, a UK-based charity focused on funding kidney disease research, reported that by 2033, the number of people affected by chronic kidney disease stages 3-5 is projected to increase to approximately 3.9 million. Consequently, the growing prevalence of kidney disease is driving the expansion of the chronic kidney disease market.

Leading companies in the chronic kidney disease market are increasingly pursuing strategic partnerships to evaluate the safety and effectiveness of advanced Automated Wearable Artificial Kidney Peritoneal Dialysis (AWAK PD) devices. Strategic partnerships involve organizations combining their expertise and resources to achieve shared objectives and long-term success. For instance, in June 2023, AWAK Technologies Pte Ltd., a Singapore-based medical technology company, partnered with Singapore General Hospital Pte Ltd. (SGH), a Singapore-based academic health science center and hospital organization. Through this collaboration, the partners aim to transform the diagnosis, treatment, and management of kidney disease by developing and testing a wearable, ultra-portable peritoneal dialysis system known as AWAK PD, which enables patients with end-stage kidney disease to receive dialysis at home and while mobile.

In January 2023, AstraZeneca Pharmaceuticals LP, a US-based biopharmaceutical company, acquired CinCor Pharma Inc. for $1.8 billion. This acquisition adds CinCor’s lead candidate, baxdrostat (CIN-107), an aldosterone synthase inhibitor designed for blood pressure control in treatment-resistant hypertension, to AstraZeneca’s cardiorenal pipeline. CinCor Pharma Inc. is a US-based clinical-stage biopharmaceutical company focused on developing therapies for resistant and uncontrolled hypertension as well as chronic kidney disease.

Major companies operating in the chronic kidney disease market are Pfizer Inc, Johnson and Johnson Services Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Bayer AG, Novartis International AG, Sanofi SA, Bristol-Myers Squibb Company, Abbott laboratories Inc., GlaxoSmithKline PLC, Takeda Pharmaceuticals Ltd., Eli Lilly and Company, Boehringer Ingelheim International GmbH, Amgen Inc., Novo Nordisk AS, Siemens Healthineers AG, AstraZeneca Pharmaceuticals LP, Teva Pharmaceutical Industries Ltd., Beckman Coulter Inc., Kissei Pharmaceutical Co. Ltd., Akebia Therapeutics Inc., Tricida Inc., Regulus Therapeutics Inc., Goldfinch Bio Co, Alio Inc., Monogram Health, Strive Health, Maze Therapeutics, ProKidney Corp.

North America was the largest region in the chronic kidney disease market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chronic kidney disease market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the chronic kidney disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the chronic kidney disease market by increasing costs of imported dialysis machines, filtration membranes, diagnostic equipment, and pharmaceutical ingredients. Healthcare providers in North America and Europe are most affected due to reliance on imported renal care technologies, while Asia-Pacific faces higher costs in device manufacturing and distribution. These tariffs are raising treatment and infrastructure costs across hospitals and dialysis centers. However, they are also encouraging local manufacturing of renal devices, domestic pharmaceutical production, and regional supply chain strengthening for kidney care solutions.

The chronic kidney disease market research report is one of a series of new reports that provides chronic kidney disease market statistics, including chronic kidney disease industry global market size, regional shares, competitors with a chronic kidney disease market share, detailed chronic kidney disease market segments, market trends and opportunities, and any further data you may need to thrive in the chronic kidney disease industry. This chronic kidney disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Chronic kidney disease is defined by the reduced ability of damaged kidneys to effectively filter blood, leading to the buildup of excess fluid and waste products in the body and potentially causing serious health complications. It is most commonly associated with conditions such as diabetes, hypertension, and obesity. The disease requires continuous and careful management and may progress to end-stage renal failure, necessitating dialysis or kidney transplantation.

The primary diagnostic methods for chronic kidney disease include blood tests, urine tests, imaging procedures, and kidney biopsy. A blood test involves the medical analysis of a blood sample to assess kidney function. Treatment options include medications, dialysis, kidney transplantation, ACE inhibitors, blood tests, and other therapies. These treatments are delivered through oral, intravenous, and subcutaneous routes of administration and are utilized by a range of end users, including hospitals and clinics, ambulatory surgery centers (ASCs), dialysis centers, and others.

The chronic kidney disease market consists of revenues earned by entities by providing peritoneal dialysis, in-center hemodialysis, and home hemodialysis. The market value includes the value of related goods sold by the service provider or included within the service offering. The chronic kidney disease market also includes sales such as captopril, enalapril, finerenone, and fosinopril used during the treatment procedure. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.